WHO 2019 nCoV Clinical 2020.5 Eng
WHO 2019 nCoV Clinical 2020.5 Eng
WHO 2019 nCoV Clinical 2020.5 Eng
WHO continues to monitor the situation closely for any changes that may affect this interim guidance. Should any factors change,
WHO will issue a further update. Otherwise, this interim guidance document will expire 2 years after the date of publication.
© World Health Organization 2020. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.
Foreword 3
Methods 3
Acknowledgements 5
Abbreviations 7
1. Background 8
2. COVID-19 care pathway (see Appendix 1) 9
3. Screening and triage: early recognition of patients with COVID-19 10
4. Immediate implementation of appropriate IPC measures 15
5. Laboratory diagnosis 16
6. Management of mild COVID-19: symptomatic treatment 17
7. Management of moderate COVID-19: pneumonia treatment 18
8. Management of severe COVID-19: severe pneumonia treatment 19
9. Management of critical COVID-19: acute respiratory distress syndrome (ARDS) 21
10. Management of critical COVID-19: septic shock 25
11. Prevention of complications in hospitalized and critically ill patients with COVID-19 28
12. Antivirals, immunomodulators and other adjunctive therapies for COVID-19 30
13. Corticosteroid therapy and COVID-19 31
14. Treatment of other acute and chronic infections in patients with COVID-19 32
15. Management of neurological and mental manifestations associated with COVID-19 33
16. Noncommunicable diseases and COVID-19 36
17. Rehabilitation for patients with COVID-19 37
18. Caring for women with COVID-19 during and after pregnancy 38
19. Feeding and caring for infants and young children of mothers with COVID-19 41
20. Caring for older people with COVID-19 44
21. Palliative care and COVID-19 45
22. Ethical principles for optimum care during the COVID-19 pandemic 46
23. Reporting of death during the COVID-19 pandemic 48
24. Clinical research during the COVID-19 pandemic 49
References 55
Methods
The original version of this document was developed in consultation with the International
Forum for Acute Care Trialists (InFACT), International Severe Acute Respiratory and
Emerging Infection Consortium (ISARIC) and the Surviving Sepsis Campaign. This is the third
edition (version 1.3) of this document, which was originally adapted from Clinical management
of severe acute respiratory infection when Middle East respiratory syndrome coronavirus
(MERS-CoV) infection is suspected (WHO, 2019).
For the development of the third version of the COVID-19 clinical guidance, we assembled a
formal Guideline Development Group (GDG) comprising individuals with broad expertise
spanning multiple specialties and all regions. Confidentiality and declarations of interest were
collected and reviewed and no conflict of interest was identified.
Because of the accelerated timeline and very broad scope of the guideline, it was not feasible
to undertake a formal GRADE process (PICO questions; systematic reviews; formal
documentation of values and preferences and incorporation of considerations of costs,
resources, and feasibility). The topics for consideration originated in the WHO interim
guidance for MERS, but for COVID-19 were greatly expanded to reflect the full spectrum of
illness, from screening to rehabilitation. Published evidence was synthesized under the
coordination of the Science Division in rapid systematic reviews, which were pre-circulated to
the GDG. The WHO Steering Committee initially drafted the recommendations about
interventions based on these reviews and input from expert clinicians participating in twice-
weekly clinical network teleconferences. The GDG held four virtual meetings via
The GREEN symbol denotes a strong recommendation or a best practice statement in favour
of an intervention.
The RED symbol denotes a recommendation or a best practice statement against an
intervention.
The YELLOW symbol denotes a conditional recommendation in favour of an intervention, or a
recommendation where special care is required in implementation.
This guidance has been significantly expanded to meet the needs of front-line clinicians caring
for patients with COVID-19 to ensure quality care. The following sections are entirely new:
COVID-19 care pathway, treatment of acute and chronic infections, management of
neurological and mental manifestations, noncommunicable diseases, rehabilitation, palliative
care, ethical priniciples, and reporting of death. The remaining sections have been
substantially expanded. Though not intended to be an exhaustive list, the following bullets
highlight some key changes:
• Discontinue transmission-based precautions (including isolation) and release from the
COVID-19 care pathway: For symptomatic patients: 10 days after symptom onset,
plus at least 3 days without symptoms (without fever and respiratory
symptoms).
• Treatment of acute co-infections: For suspected or confirmed mild COVID-19,
against the use of antibiotic therapy or prophylaxis. For suspected or confirmed
moderate COVID-19, that antibiotics should not be prescribed unless there is
clinical suspicion of a bacterial infection.
• Prevention of complications: In patients (adults and adolescents) hospitalized with
COVID-19, use pharmacological prophylaxis, such as low molecular weight
heparin (e.g. enoxaparin), according to local and international standards, to
prevent venous thromboembolism, when not contraindicated. For those with
contraindications, use mechanical prophylaxis (intermittent pneumatic
compression devices).
And, importantly, key previous recommendations that remain are:
• Antivirals, immunomodulators and other adjunctive therapies: WHO recommends that the
listed drugs not be administered as treatment or prophylaxis for COVID-19, outside the
context of clinical trials.
• Corticosteroids and COVID-19: WHO recommends against the routine use of
systemic corticosteroids for treatment of viral pneumonia.
Developed by a multidisciplinary panel of health care providers with experience in the clinical
management of patients with COVID-19 and other viral infections, including severe acute
respiratory virus (SARS) and Middle East respiratory virus (MERS), as well as sepsis and
Acknowledgements
WHO: Janet V Diaz (Lead), April Baller, Anshu Banerjee, Silvia Bertagnolio, Mercedes Bonet,
Andrea Bosman, Marie-Charlotte Bousseau, Maurice Bucagu, Neerja Chowdhary, Jane
Cunningham, Meg Doherty, Tarun Dua, Nathan Ford, Laurence Grummer-Strawn, Fahmy
Hanna, Benedikt Huttner, Ernesto Jaramillo, Maria Van Kerkhove, Caron Kim, Kavitha
Kolappa, Teresa Kortz, Ornella Lincetto, Jody-Ann Mills, Lorenzo Moja, Susan Norris, Olufemi
Oladapo, Peter Olumese, Mark van Ommeren, Martina Penazzato, Anayda Portela, Andreas
Reis, Pryanka Relan, Lisa Rogers, Nigel Rollins, Ingrid Smith, Howard Sobel, Maria Pura
Solon, Yuka Sumi, Anna Thorson, Kavita Trivedi, Marco Vitoria, Prinzo Weise, Wilson Were,
Matteo Zignol.
Special thanks also go to the WHO COVID-19 IPC Global Expert Panel for their input.
While most people with COVID-19 develop only mild (40%) or moderate (40%) disease (see
Table 2), approximately 15% develop severe disease that requires oxygen support, and 5%
have critical disease with complications such as respiratory failure, acute respiratory distress
syndrome (ARDS), sepsis and septic shock, thromboembolism, and/or multiorgan failure,
including acute kidney injury and cardiac injury (14). Older age, smoking (15, 16) and
underlying noncommunicable diseases (NCDs), such as diabetes, hypertension, cardiac
disease, chronic lung disease and cancer, have been reported as risk factors for severe
disease and death, and multivariable analyses have confirmed older age, higher sequential
organ failure assessment (SOFA) score and D-dimer > 1 µg/L on admission were associated
with higher mortality (17, 18) (see Table 2). This study also observed a median duration of
viral RNA detection of 20.0 days (IQR 17.0–24.0) in survivors, but COVID-19 viral RNA was
detectable until death in non-survivors. The longest observed duration of viral RNA detection
in survivors was 37 days (17, 18).
There are few data on the clinical presentation of COVID-19 in specific populations, such as
children and pregnant women. Clinical manifestations of COVID-19 are generally milder in
children compared with adults (27-30). Relatively few cases of infants confirmed with
COVID-19 have been reported; infants also experience mild illness (29). However, most
recently, an acute presentation with a hyperinflammatory syndrome leading to multiorgan
failure and shock has been described (31), now described as multisystem inflammatory
syndrome temporally associated with COVID-19 in children and adolescents. Robust
evidence associating underlying conditions with severe illness in children is still lacking.
Among 345 children with laboratory-confirmed COVID-19 and complete information about
underlying conditions, 23% had an underlying condition, with chronic lung disease (including
asthma), cardiovascular disease and immunosuppression most commonly reported (32).
A person enters the COVID-19 care pathway after s/he is screened, based on a
standardized case definition, including assessment of symptoms, and meets
criteria for a suspect case.
• Probable cases are suspect cases for whom testing for SARS-CoV-2 is
inconclusive or not available.
Remarks:
2. Considerations for co-infections and/or chronic diseases must be made within the
COVID-19 care pathway.
3. All suspect cases should be tested to determine if they are a confirmed case. Until
proven negative, all suspected cases should remain in the COVID-19 care pathway. If
testing is not available, the person becomes a probable case (based on clinical
suspicions) and should be cared for in the COVID-19 pathway.
Remarks:
2. Please note that the clinical pathway needs to be clearly outlined by countries to follow
each patient until outcome, including full recovery. Discharge criteria from clinical care
need to take into account the patient’s condition, disease experience and other factors.
3. Release from the COVID-19 care pathway is not the same as clinical discharge from a
facility or from one ward to another. For example, some patients may still require ongoing
rehabilitation, or other aspects of care, beyond release from the COVID-19 care pathway,
based on clinical needs in the COVID-19 care pathway. If release from the COVID-19
care pathway coincides with clinical discharge, then several clinical considerations, such
as medication reconciliation, plan for follow up with clinical provider in place, review of
routine immunization status, among others, should be taken into account.
We recommend screening all persons at the first point of contact with the
health system in order to identify individuals that have suspected or confirmed
COVID-19.
Remarks:
3. In areas with other endemic infections that cause fever, such as malaria, dengue,
tuberculosis (TB) etc., as part of screening, febrile patients should be tested as per
routine protocols (37-41), irrespective of the presence of respiratory signs and symptoms.
Co-infection with COVID-19 may coexist.
4. Large outbreaks have been observed in long-term care facilities (LTCFs) (35). The
COVID-19 care pathway should be activated for all residents of LTCFs who are contacts
of a confirmed case in that LTCF, including immediate isolation, testing and treatment as
needed. The priority focus in these settings should be to ensure the well-being of
residents and protect health workers, and implementation of clinical management and
IPC that considers the individual’s condition and prognosis (such as screening visitors for
COVID-19) (42).
Remarks:
1. Patients with mild and moderate illness may not require emergency interventions or
hospitalization; however, isolation is necessary for all suspect or confirmed cases to
contain virus transmission. The decision to monitor a suspect case in a health facility,
community facility or home should be made on a case-by-case basis. This decision will
depend on the clinical presentation, requirement for supportive care, potential risk factors
for severe disease, and conditions at home, including the presence of vulnerable persons
in the household.
2. Some patients develop severe pneumonia and require oxygen therapy, and a minority
progress to critical disease with complications such as respiratory failure or septic shock
(46, 47) (see Table 2). Early identification of patients with severe disease allows for rapid
initiation of optimized supportive care treatments and safe, rapid referral to a designated
destination in the COVID-19 care pathway (with access to oxygen and respiratory
support).
4. Children with suspected or confirmed COVID-19 infection should be kept together with
caregivers wherever possible (if caregivers also have suspected or confirmed COVID-19
infection), and cared for in child-friendly spaces, taking into account specific medical,
nursing, nutritional, and mental health and psychosocial support needs of children.
Most persons experience fever (83–99%), cough (59–82%), fatigue (44–70%), anorexia
(40–84%), shortness of breath (31–40%), myalgias (11–35%). Other non-specific symptoms,
such as sore throat, nasal congestion, headache, diarrhoea, nausea and vomiting, have also
been reported (17, 48-50). Loss of smell (anosmia) or loss of taste (ageusia) preceding the
onset of respiratory symptoms has also been reported (19, 51, 52).
Older people and immunosuppressed patients in particular may present with atypical
symptoms such as fatigue, reduced alertness, reduced mobility, diarrhoea, loss of appetite,
delirium, and absence of fever (34-36).
Children might not have reported fever or cough as frequently as adults (32).
Risk factors for severe Age more than 60 years (increasing with age).
disease
Underlying noncommunicable diseases (NCDs): diabetes, hypertension, cardiac disease,
––
chronic lung disease, cerebrovascular disease, chronic kidney disease, immunosuppression
and cancer have been associated with higher mortality.
Smoking.
Mild Symptomatic patients (Table 1) meeting the case definition for COVID-19
disease without evidence of viral pneumonia or hypoxia.
See the WHO website for most up-to-date case definitions (1).
Moderate Pneumonia Adolescent or adult with clinical signs of pneumonia (fever, cough,
disease dyspnoea, fast breathing) but no signs of severe pneumonia, including SpO2
≥ 90% on room air (54).
Critical Acute respiratory Onset: within 1 week of a known clinical insult (i.e. pneumonia) or new or
disease distress worsening respiratory symptoms.
syndrome (ARDS)
(57-59)
Chest imaging: (radiograph, CT scan, or lung ultrasound): bilateral opacities,
not fully explained by volume overload, lobar or lung collapse, or nodules.
Critical Sepsis (3,4) Adults: acute life-threatening organ dysfunction caused by a dysregulated
disease host response to suspected or proven infection. Signs of organ dysfunction
include: altered mental status, difficult or fast breathing, low oxygen saturation,
–– output (3), fast heart rate, weak pulse, cold extremities or low
reduced urine
blood pressure, skin mottling, laboratory evidence of coagulopathy,
thrombocytopenia, acidosis, high lactate, or hyperbilirubinemia.
Children: any hypotension (SBP < 5th centile or > 2 SD below normal for
age) or two or three of the following: altered mental status; bradycardia or
tachycardia (HR < 90 bpm or > 160 bpm in infants and heart rate < 70 bpm
or > 150 bpm in children); prolonged capillary refill (> 2 sec) or weak pulse;
fast breathing; mottled or cool skin or petechial or purpuric rash; high
lactate; reduced urine output; hyperthermia or hypothermia (60, 61).
Abbreviations: BP blood pressure; bpm beats per minute; CPAP continuous positive airway pressure; CT computed
tomography; FiO2 fraction of inspired oxygen; MAP mean arterial pressure; NIV non-invasive ventilation; OI Oxygenation
Index; OSI Oxygenation Index using SpO2; PaO2 partial pressure arterial oxygen; PEEP positive end-expiratory pressure;
SBP systolic blood pressure; SD standard deviation; SIRS systemic inflammatory response syndrome; SOFA sequential
organ failure assessment; SpO2 oxygen saturation.
Table 3. How to implement IPC measures for patients with suspected or confirmed
COVID-19 (63)
Contact precautions include gloves and disposable gown. Droplet precautions prevent large droplet
transmission of respiratory viruses, and include medical mask and eye protection. Use a medical mask if
working within 1 m of the patient. When providing care in close contact with a suspect or confirmed COVID-
19 patient use eye protection (face mask or goggles), because sprays of secretions may occur. In particular,
use a combination of PPE for contact and droplet precautions (medical mask, eye protection, gloves and
gown) when entering room and remove PPE when leaving. Carefully practise hand hygiene using an alcohol-
based hand rub if hands are not visibly dirty or soap and water and disposable towels, before PPE use and
after PPE removal, and when indicated while providing care, according to the WHO Five Moments for hand
hygiene (64). If possible, use either disposable or dedicated equipment (e.g. stethoscopes, blood pressure
cuffs, pulse oximeters and thermometers). If equipment needs to be shared among patients, clean and
disinfect between each patient use. Ensure that health care workers avoid contaminating environmental
surfaces that are not directly related to patient care (e.g. door handles and light switches) and refrain from
touching their eyes, nose and mouth with potentially contaminated gloved or ungloved hands.
Place all cases in single rooms, or separately group together those with same etiologic diagnosis, such as
suspect cases with suspects; probable cases with probable; and confirmed cases with confirmed. In other
words, if an etiological diagnosis is not possible, group patients with similar clinical diagnosis and based on
epidemiological risk factors. Keep at at least 1 m spatial separation between cases. Suspected or probable
cases should not be cohorted together with confirmed cases. Limit patient movement within the institution
and ensure that patients wear medical masks when outside their rooms.
Because of uncertainty around the potential for aerosolization, high-flow nasal oxygen (HFNO), NIV,
including bubble CPAP, should be used with airborne precautions until further evaluation of safety can be
completed. There is insufficient evidence to classify nebulizer therapy as an aerosol-generating procedure
that is associated with transmission of COVID-19. More research is needed.
Note: In situations where TB may co-exist, specific measures may be necessary in addition to the above (65).
We recommend, for all suspect cases, collection of upper respiratory tract (URT)
specimens (nasopharyngeal and oropharyngeal) for testing by reverse
transcription polymerase chain reaction (RT-PCR) and, where clinical suspicion
remains and URT specimens are negative, to collect specimens from the lower
respiratory tract (LRT) when readily available (expectorated sputum, or
endotracheal aspirate/bronchoalveolar lavage in ventilated patient). In addition,
testing for other respiratory viruses and bacteria should be considered when
clinically indicated.
Remarks:
1. Use appropriate PPE for specimen collection (droplet and contact precautions for URT
specimens; airborne precautions for LRT specimens). When collecting URT samples,
use viral swabs (sterile Dacron or rayon, not cotton) and viral transport media. Do not
sample the nostrils or tonsils. In a patient with suspected COVID-19, especially with
pneumonia or severe illness, a single negative URT sample does not exclude the
diagnosis, and additional URT and LRT samples are recommended. LRT (vs URT)
samples are more likely to be positive and for a longer period. Clinicians may elect to
collect only LRT samples when these are readily available (for example, in mechanically
ventilated patients). Sputum induction should be avoided owing to increased risk of
aerosol transmission.
2. In hospitalized patients with confirmed COVID-19, repeated URT and LRT samples can
be collected, as clinically indicated, but are no longer indicated for release from COVID-
19 precautions. The frequency of specimen collection will depend on local epidemic
characteristics and resources.
Depending on local epidemiology and clinical symptoms, test for other potential
etiologies (e.g. malaria, dengue fever, typhoid fever) as appropriate.
Remarks:
1. Dual infections with other respiratory infections (viral, bacterial and fungal) have been
found in COVID-19 patients (67). As a result, a positive test for a non-COVID-19
pathogen does not rule out COVID-19, or vice versa. At this stage, detailed microbiologic
studies are needed in all suspected cases. Both URT and LRT specimens can be tested
for other respiratory viruses, such as influenza A and B (including zoonotic influenza A),
respiratory syncytial virus, parainfluenza viruses, rhinoviruses, adenoviruses,
enteroviruses (e.g. EVD68), human metapneumovirus and endemic human
coronaviruses (i.e. HKU1, OC43, NL63, and 229E). LRT specimens can also be tested
for bacterial pathogens, including Legionella pneumophila.
For COVID-19 patients with severe or critical disease, also collect blood cultures,
ideally prior to initiation of antimicrobial therapy (3).
Remarks:
1. In areas with other endemic infections that cause fever (such as malaria, dengue, etc.),
febrile patients should be tested and treated for those endemic infections per routine
protocols (37, 40), irrespective of the presence of respiratory signs and symptoms. Co-
infection with COVID-19 may occur.
2. The decision to monitor a suspect case with mild COVID-19 in a health facility,
community facility or home should be made on a case-by-case basis based on the local
COVID-19 care pathway. Additionally, this decision may depend on the clinical
presentation, requirement for supportive care, potential risk factors for severe disease,
and conditions at home, including the presence of vulnerable persons in the household.
3. If managed at home in self-isolation, refer to WHO guidance on Home care for patients
with COVID-19 presenting with mild symptoms and management of their contacts (70).
Remark:
At present, there is no evidence to indicate that there are severe adverse events in patients with
COVID-19 as a result of the use of non-steroidal anti-inflammatory drugs (71).
Remark:
Patients with risk factors for severe illness should be monitored closely, given the possible risk of
deterioration. If they develop any worsening symptoms (such as light headedness, difficulty
breathing, chest pain, dehydration, etc.), they should seek urgent care through the established
COVID-19 care pathway. Caregivers of children with mild COVID-19 should monitor for signs and
symptoms of clinical deterioration requiring urgent re-evaluation. These include difficulty
breathing/fast or shallow breathing (for infants: grunting, inability to breastfeed), blue lips or face,
chest pain or pressure, new confusion, inability to awaken/not interacting when awake, inability to
drink or keep down any liquids. Consider alternative delivery platforms such as home-based, phone,
telemedicine or community outreach teams to assist with monitoring (72).
Remark:
Widespread use of antibiotics should be discouraged, as their use may lead to higher bacterial
resistance rates, which will impact the burden of disease and deaths in a population during the
COVID-19 pandemic and beyond (73, 74).
Remark:
In areas with other endemic infections that cause fever (such as malaria, dengue, etc.), febrile
patients should be tested and treated for those endemic infections per routine protocols (37, 40, 41),
irrespective of the presence of respiratory signs and symptoms. Co-infection with COVID-19 may
occur.
1. Few patients with COVID-19 experience a secondary bacterial infection. A recent systematic
review of patients hospitalized with COVID-19 reported only 8% were reported as experiencing
bacterial/fungal co-infection during hospital admission (75).
2. Consider in older people, particularly those in LTCFs, and children < 5 years of age, to provide
empiric antibiotic treatment for possible pneumonia (73, 74). As these patients are not
hospitalized, treatment with Access antibiotics (such as co-amoxicillin) is adequate, instead of
broad-spectrum antibiotics (Watch and Reserve antibiotics) (76).
Remarks:
1. For patients being treated at home, counselling regarding signs and symptoms of complications
(such as difficulty breathing, chest pain, etc.) should be provided to patients and their
caregivers. If they develop any of these symptoms, they should seek urgent care through the
established COVID-19 care pathway. At this time, there is no evidence to guide the use of pulse
oximeters in home settings. Consider alternative delivery platforms such as home-based,
phone, telemedicine or community outreach teams to assist with monitoring.
2. For hospitalized patients, regularly monitor vital signs (including pulse oximetry) and, where
possible, utilize medical early warning scores (e.g. NEWS2, PEWS) that facilitate early
recognition and escalation of treatment of the deteriorating patient (77).
All areas where severe patients may be cared for should be equipped with pulse
oximeters, functioning oxygen systems and disposable, single-use, oxygen-delivering
interfaces (nasal cannula, Venturi mask, and mask with reservoir bag).
Remark:
This includes areas in any part of health facilities, including emergency units, critical care units,
primary care/outpatient clinics, as well as pre-hospital settings and ad hoc community facilities that
may receive patients with severe COVID-19. See WHO Oxygen sources and distribution for COVID-
19 treatment centres (78).
Remarks:
1. Adults with emergency signs (obstructed or absent breathing, severe respiratory distress,
central cyanosis, shock, coma and/or convulsions) should receive emergency airway
management and oxygen therapy during resuscitation to target SpO2 ≥ 94% (44, 79). Once the
2. Children with emergency signs (obstructed or absent breathing, severe respiratory distress,
central cyanosis, shock, coma or convulsions) should receive emergency airway management
and oxygen therapy during resuscitation to target SpO2 ≥ 94% (44, 79, 80). Once patient is
stable, the target is > 90% SpO2 (80). Use of nasal prongs or nasal cannula is preferred in
young children, as they may be better tolerated.
3. In adults, techniques such as positioning, e.g. high supported sitting, may help to optimize
oxygenation, ease breathlessness and reduce energy expenditure (81). Prone position for
awake, spontaneously breathing patients may also improve oxygenation and the
ventilation/perfusion ratio, but evidence is lacking and should be done under clinical trial
protocol to assess efficacy and safety.
4. In adult patients with evidence of increased secretion production, secretion retention, and/or
weak cough, airway clearance management may assist with secretion clearance. Techniques
include gravity-assisted drainage and active cycles of breathing technique. Devices including
mechanical insufflation-exsufflation and inspiratory positive pressure breathing should be
avoided where possible. Implementation of techniques should be tailored to the individual
patient and follow available guidelines (81).
Remarks:
1. Patients hospitalized with COVID-19 require regular monitoring of vital signs (including pulse
oximetry) and, where possible, utilization of medical early warning scores (e.g. NEWS2, PEWS)
that facilitate early recognition and escalation of treatment of the deteriorating patient (77).
2. Haematology and biochemistry laboratory testing and electrocardiogram and chest imaging
should be performed at admission and as clinically indicated to monitor for complications, such
as acute respiratory distress syndrome and acute liver injury, acute kidney injury, acute cardiac
injury, disseminated intravascular coagulation (DIC) and/or shock. Application of timely, effective
and safe supportive therapies is the cornerstone of therapy for patients who develop severe
manifestations of COVID-19.
3. Monitor patients with COVID-19 for signs or symptoms suggestive of venous or arterial
thromboembolism, such as stroke, deep venous thrombosis, pulmonary embolism or acute
coronary syndrome, and proceed according to hospital protocols for diagnosis (such as
laboratory tests and/or imaging) and further management.
4. After resuscitation and stabilization of the pregnant woman, fetal well-being should be
monitored. The frequency of fetal heart rate observations should be individualized based on
gestational age, maternal clinical status (e.g. hypoxia) and fetal conditions.
Remark:
Patients with COVID-19 should be treated cautiously with intravenous fluids; aggressive fluid
resuscitation may worsen oxygenation, especially in settings where there is limited availability of
mechanical ventilation (82). This applies to both children and adults.
The following recommendations pertain to adult and paediatric patients with mild
ARDS who are treated with non-invasive or high-flow nasal oxygen (HFNO) systems.
In selected patients with COVID-19 and mild ARDS, a trial of HFNO, non-invasive
ventilation – continuous positive airway pressure (CPAP), bilevel positive airway
pressure (BiPAP) may be used. Refer to Table 2 for definitions of mild, moderate and
severe ARDS.
Remarks:
1. Patients with hypoxaemic respiratory failure and haemodynamic instability, multiorgan failure or
abnormal mental status should not receive HFNO or NIV in place of other options such as
invasive ventilation.
2. Patients receiving a trial of HFNO or NIV should be in a monitored setting and cared for by
personnel experienced with HFNO and/or NIV and capable of performing endotracheal
intubation in case the patient acutely deteriorates or does not improve after a short trial (about 1
hour). Intubation should not be delayed if the patient acutely deteriorates or does not improve
after a short trial.
3. Adult HFNO systems can deliver 60 L/min of gas flow and FiO2 up to 1.0. Paediatric circuits
generally only handle up to 25 L/min, and many children will require an adult circuit to deliver
adequate flow. When considering delivering HFNO or NIV outside the usual care settings,
evaluating oxygen capacity is important to ensure the higher flow rates required for these
devices can be maintained. See WHO Oxygen sources and distribution for COVID-19 treatment
centres (78).
4. Because of uncertainty around the potential for aerosolization, HFNO, NIV, including bubble
CPAP, should be used with airborne precautions until further evaluation of safety can be
completed. If these interventions are performed outside of private rooms in ICUs with
appropriate ventilation systems installed, then cohorting of patients requiring these interventions
in designated wards will facilitate the implementation of airborne precautions, ensuring all staff
entering wear appropriate PPE and adequate environmental ventilation is ensured.
6. NIV guidelines make no recommendation on use in hypoxaemic respiratory failure (apart from
cardiogenic pulmonary oedema, postoperative respiratory failure and early NIV for
immunocompromized patients) or pandemic viral illness (referring to studies of SARS and
pandemic influenza) (83). Risks include delayed intubation, large tidal volumes, and injurious
transpulmonary pressures. Limited data suggest a high failure rate in patients with other viral
infections such as MERS-CoV who receive NIV (86).
7. In situations where mechanical ventilation might not be available, bubble nasal CPAP may be a
more readily available alternative for newborns and children with severe hypoxaemia (87).
The following recommendations pertain to adult and paediatric patients with ARDS
who need intubation and invasive mechanical ventilation.
Remark:
Patients may continue to have increased work of breathing or hypoxaemia even when oxygen is
delivered via a face mask with reservoir bag (flow rates of 10–15 L/min, which is typically the
minimum flow required to maintain bag inflation; FiO2 0.60–0.95). Hypoxaemic respiratory failure in
ARDS commonly results from intrapulmonary ventilation-perfusion mismatch or shunt and usually
requires mechanical ventilation (3).
Remark:
Patients with ARDS, especially young children or those who are obese or pregnant, may desaturate
quickly during intubation. Pre-oxygenation with 100% FiO2 for 5 minutes, and use of a face mask
with reservoir bag is preferred. When possible, avoid bag-valve mask ventilation to reduce exposure
to aerosols. Rapid-sequence intubation is appropriate after an airway assessment that identifies no
signs of difficult intubation (88-90).
The implementation of mechanical ventilation using lower tidal volumes and lower inspiratory
pressures is a strong recommendation from a clinical guideline for patients with ARDS (3),
and is also suggested for patients with sepsis-induced respiratory failure who do not meet
ARDS criteria (3). The initial target tidal volume is 6 mL/kg PBW; tidal volume up to 8 mL/kg
PBW is allowed if undesirable side-effects occur (e.g. dyssynchrony, pH < 7.15). Permissive
hypercapnia is permitted. Ventilator protocols are available (91). The use of deep sedation
may be required to control respiratory drive and achieve tidal volume targets.
In children, a lower level of plateau pressure (< 28 cmH2O) is targeted, and a lower target of
pH is permitted (7.15–7.30). Tidal volumes should be adapted to disease severity: 3–6 mL/kg
PBW in the case of poor respiratory system compliance, and 5–8 mL/kg PBW with better
preserved compliance (92).
In adult patients with severe ARDS (PaO2/FiO2 < 150) prone ventilation for 12–16
hours per day is recommended.
Remarks:
1. Application of prone ventilation is recommended for adult patients, preferably for 16 hours per
day, and may be considered for paediatric patients with severe ARDS but requires sufficient
human resources and expertise to be performed safely; protocols (including videos) are
available (93, 94).
2. There is little evidence on prone positioning in pregnant women with ARDS; this could be
considered in early pregnancy. Pregnant women in the third trimester may benefit from being
placed in the lateral decubitus position.
This has also been recommended in another international guideline (3). The main effect is to
shorten the duration of ventilation. A sample protocol for implementation of this
recommendation is available (95).
Remarks:
1. PEEP titration requires consideration of benefits (reducing atelectrauma and improving alveolar
recruitment) versus risks (end-inspiratory overdistension leading to lung injury and higher
pulmonary vascular resistance). Tables are available to guide PEEP titration based on the FiO2
Remark:
A trial found that this strategy improved survival in adult patients with moderate-severe ARDS
(PaO2/FiO2 < 150) without causing significant weakness (100), but results of a recent larger trial
found that use of neuromuscular blockade with high PEEP strategy was not associated with a
survival benefit when compared with a light sedation strategy without neuromuscular blockade
(101). Intermittent or continuous neuromuscular blockade may still be considered in patients with
ARDS, both adults and children, in certain situations: ventilator dyssynchrony despite sedation,
such that tidal volume limitation cannot be reliably achieved; or refractory hypoxaemia or
hypercapnia.
Avoid disconnecting the patient from the ventilator, which results in loss of
PEEP, atelectasis and increased risk of infection of health care workers.
Remarks:
1. Use in-line catheters for airway suctioning and clamp endotracheal tube when disconnection
is required (for example, transfer to a transport ventilator).
An RCT of ECMO for adult patients with ARDS was stopped early and found no statistically
significant difference in the primary outcome of 60-day mortality between ECMO and standard
medical management (including prone positioning and neuromuscular blockade) (102). However,
ECMO was associated with a reduced risk of the composite outcome that consisted of mortality
and crossover to ECMO treatment (104), and a post-hoc Bayesian analysis of this RCT showed
that ECMO is very likely to reduce mortality across a range of prior assumptions (212). In patients
with MERS, ECMO vs conventional treatment was associated with reduced mortality in a cohort
study (2). ECMO is a resource-intensive therapy and should be offered only in expert centres with
a sufficient case volume to maintain expertise and staff volume and capacity to apply the IPC
measures required (103, 104). In children, ECMO can also be considered in those with severe
ARDS, although high-quality evidence for benefit is lacking (92).
Remarks:
1. In the absence of a lactate measurement, use blood pressure (i.e. MAP) and clinical signs of
perfusion to define shock.
2. Standard care includes early recognition and the following treatments to be done
immediately, within 1 hour of recognition: antimicrobial therapy, and initiation of fluid bolus
and vasopressors for hypotension (3). The use of central venous and arterial catheters
should be based on resource availability and individual patient needs. Detailed guidelines
from the Surviving Sepsis Campaign and WHO are available for the management of septic
shock in adults (3) and children (55, 105). Alternate fluid regimens are suggested when caring
for adults and children in resource-limited settings (106, 107).
In resuscitation for septic shock in children, give 10–20 mL/kg crystalloid fluid
as a bolus in the first 30–60 minutes.
Remarks:
2. Determine the need for additional fluid boluses (250–500 mL in adults; 10–20 mL/kg in
children) based on clinical response and improvement of perfusion targets and reassess for
signs of fluid overload after each bolus. Perfusion targets include MAP (> 65 mmHg or age-
appropriate targets in children), urine output (> 0.5 mL/kg/hr in adults; 1 mL/kg/hr in children),
and improvement of skin mottling and extremity perfusion, capillary refill, heart rate, level of
consciousness, and lactate.
4. In pregnant women, compression of the inferior vena cava can cause a decrease in venous
return and cardiac preload and may result in hypotension. For this reason, pregnant women
with sepsis and or septic shock may need to be placed in the lateral decubitus position to
off-load the inferior vena cava (108).
Remark:
Starches are associated with an increased risk of death and acute kidney injury compared with
crystalloids. The effects of gelatins are less clear, but they are more expensive than crystalloids
(3, 109). Hypotonic (vs isotonic) solutions are less effective at increasing intravascular volume.
Surviving Sepsis guidelines also suggest albumin for resuscitation when patients require
substantial amounts of crystalloids, but this conditional recommendation is based on low-quality
evidence (3).
Remarks:
1. Vasopressors (i.e. norepinephrine, epinephrine, vasopressin and dopamine) are most safely
given through a central venous catheter at a strictly controlled rate, but it is also possible to
safely administer them via peripheral vein (110) and intraosseous needle. Monitor blood
pressure frequently and titrate the vasopressor to the minimum dose necessary to maintain
perfusion and prevent side-effects. A recent study suggests that in adults 65 years or older a
MAP 60–65 mmHg target is equivalent to ≥ 65 mmHg (111).
Remark:
Thromboembolism
Coagulopathy is common in patients with severe COVID-19, and both venous and arterial
thromboembolism have been reported (23, 24, 112-114).
Remarks:
2. Use medications that carry the least risk possible for drug-drug interactions with other
medications the person may be receiving. Psychotropic medications with sedative proprieties,
such as benzodiazepines, can worsen respiratory function. Some, psychotropic medications
have QTc-prolonging activity (such as some antipsychotics and some antidepressants). Use
medications that carry the least risk possible for side-effects that may worsen COVID-19
symptomatology, including sedation, respiratory or cardiac function, risk of fever or other
immunological abnormalities, or coagulation abnormalities.
Other complications
These interventions are based on Surviving Sepsis (3) or other guidelines (116-119), and are
generally limited to feasible recommendations based on high-quality evidence. Recent
publications have encouraged best practices to continue during the COVID-19 outbreak (120).
See the WHO Clinical care for severe acute respiratory infection toolkit: COVID-19 adaptation
for practical tools to assist implementation (45).
Reduce incidence of • Oral intubation is preferable to nasal intubation in adolescents and adults
ventilator-associated
• Keep patient in semi-recumbent position (head of bed elevation 30–45º)
pneumonia
• Use a closed suctioning system; periodically drain and discard condensate
in tubing
• Use a new ventilator circuit for each patient; once patient is ventilated,
change circuit if it is soiled or damaged, but not routinely
• Change heat moisture exchanger when it malfunctions, when soiled, or
every 5–7 days
Reduce incidence • Use a checklist with completion verified by a real-time observer as a
of catheter-related reminder of each step needed for sterile insertion and as a daily reminder
bloodstream to remove catheter if no longer needed
infection
Remarks:
1. Existing published literature on the agents listed above is mostly observational in nature, with
few clinical trials; and does not provide high-quality evidence in favour of any of these
agents. In addition, important side-effects have been described (122-131).
• Chloroquine and hydroxychloroquine +/- azithromycin: each can cause QT
prolongation and taken together can increase the risk of cardiotoxicity.
• Lopinavir/ritonavir: the most common adverse effects are gastrointestinal.
• Remdesivir: elevation of hepatic enzymes, GI complications, rash, renal impairment
and hypotension.
• Umifenovir: diarrhoea, nausea.
• Favipiravir: QT interval prolongation.
• Interferon-β-1a: pyrexia, rhabdomyolysis.
• Tocilizumab: URT infections, nasopharyngitis, headache, hypertension, increased
alanine aminotransferase (ALT), injection site reactions.
2. This recommendation has not changed and is consistent with previous WHO guidance
documents and other international grade-based guidelines (132).
3. Outside of clinical trials, the following criteria should be met for access to investigational
therapeutics: 1) no proven effective treatment exists; 2) it is not possible to initiate clinical
studies immediately; 3) data providing preliminary support of the intervention’s efficacy
and safety are available, at least from laboratory or animal studies, and use of the
intervention outside clinical trials has been suggested by an appropriately qualified
scientific advisory committee on the basis of a favourable risk–benefit analysis; 4) the
relevant country authorities, as well as an appropriately qualified ethics committee, have
approved such use; 5) adequate resources are available to ensure that risks can be
minimized; 6) the patient’s informed consent is obtained; and 7) the emergency use of the
intervention is monitored and the results are documented and shared in a timely manner
with the wider medical and scientific community (133).
Remarks:
2. Given the lack of effectiveness and possible harm, routine corticosteroids should be avoided
unless they are indicated for another reason. Other reasons may include exacerbation of
asthma or chronic obstructive pulmonary disease (COPD), septic shock or ARDS, and
risk/benefit analysis needs to be conducted for individual patients.
3. A recent guideline issued by an international panel and based on the findings of two recent
large RCTs makes a conditional recommendation for corticosteroids for all patients with
sepsis (including septic shock) (139). Surviving Sepsis guidelines, written before these RCTs
were reported, recommend corticosteroids only for patients in whom adequate fluids and
vasopressor therapy do not restore haemodynamic stability (3). In addition, a recent trial
reported that corticosteroids may reduce mortality in moderate-severe ARDS (140). Clinicians
considering corticosteroids for a patient with COVID-19 and sepsis must balance the potential
small reduction in mortality with the potential downside of prolonged shedding of coronavirus
in the respiratory tract, as has been observed in patients with MERS (84, 138, 141). If
corticosteroids are prescribed, monitor and treat hyperglycaemia, hypernatraemia and
hypokalaemia. Monitor for recurrence of inflammation and signs of adrenal insufficiency after
stopping corticosteroids, which may have to be tapered. Because of the risk of Strongyloides
stercoralis hyperinfection with steroid therapy, diagnosis or empiric treatment should be
considered in endemic areas if steroids are used (142).
4. WHO recommends antenatal corticosteroid therapy for women at risk of preterm birth from 24
to 34 weeks of gestation when there is no clinical evidence of maternal infection, and
adequate childbirth and newborn care is available. However, in cases where the woman
presents with mild COVID-19, the clinical benefits of antenatal corticosteroid might outweigh
the risks of potential harm to the mother. In this situation, the balance of benefits and harms
for the woman and the preterm newborn should be discussed with the woman to ensure an
informed decision, as this assessment may vary depending on the woman’s clinical condition,
her wishes and that of her family, and available health care resources.
The prevalence of acute co-infections or secondary infections coinciding with COVID-19 has
been not adequately described but appears to be low (75), and will be based on local factors
and endemic or other emerging infections (48, 73, 74, 121). Antibiotic overuse increases the
risk of emergence and transmission of multidrug-resistant bacteria. Infections with multidrug-
resistant bacteria are more difficult to treat, and associated with increased morbidity and
mortality.
Acute co-infections
Remarks:
1. For patients with severe disease, early and appropriate empiric antimicrobial therapy (3) can
be administered in the emergency unit and/or pre-hospital setting. Empiric antibiotic
treatment should be based on the clinical diagnosis (community-acquired pneumonia, health
care-associated pneumonia [if infection was acquired in health care setting] or sepsis), local
epidemiology and susceptibility data, and national treatment guidelines. Choose antibiotics
with the least ecologic impact based on data and guidance from your own institution, region
or country (e.g. of the Access group of the AWaRe classification) (76). The AWaRe
classification categorizes antibiotics into three different groups (Access, Watch and Reserve)
based on their indication for common infectious syndromes, their spectrum of activity, and
their potential for increasing antibiotic resistance. The AWaRe classification is a tool for
antibiotic stewardship at local, national and global levels with the aim of optimizing antibiotic
use and reducing antibiotic resistance.
4. Duration of empiric antibiotic treatment should be as short as possible; generally 5–7 days.
5. An increase in antibiotic use during the pandemic may cause adverse reactions such as
Clostridioides difficile infections, with clinical disease ranging from diarrhoea and fever to
colitis (144). Antibiotic stewardship programmes should be put into place or continue among
COVID-19 patients.
Chronic infections
It is currently unknown whether immunosuppression caused by chronic co-infections such as
human immunodeficiency virus (HIV) puts persons at greater risk for severe COVID-19
disease. However, people living with HIV with advanced disease have an increased risk of
opportunistic infections (notably TB) and related complications in general. Facility-based HIV
testing services should continue and those newly diagnosed should start antiretroviral
therapy as soon as possible. For people living with HIV already on treatment, continuity of
antiretroviral therapy and prophylaxis for co-infections is essential, with multi-month
prescribing.
People with COVID-19 are at high risk for delirium, and sometimes delirium may be a presenting
feature without respiratory symptoms (see Chapter 3). Anxiety and depressive symptoms may
constitute common reactions for people in the context of COVID-19 diagnosis, especially for those
who may be hospitalized, due to concerns for one’s own health or the health of others, the need for
physical isolation (which can lead to social isolation), potential risk of death, concerns over the risk
of infecting others, and concerns over leaving family members alone who may need care. Stressors
particular to COVID-19 include: fear of falling ill and dying, fear of being socially excluded/placed in
quarantine, loss of livelihood and loss of loved ones, and feelings of helplessness, boredom and
loneliness due to being isolated. These stressors may trigger new symptoms or exacerbate
underlying mental or neurological conditions. Patients with pre-existing mental health conditions and
substance abuse disorders may also be adversely impacted. People with COVID-19 are at higher
risk for sleep problems owing to acute stress responses, as well as additional reasons for those who
are hospitalized such as environmental factors, invasive medical procedures (e.g. mechanical
ventilation) and the frequent combination of multiple medications possibly disrupting sleep patterns
(145, 146).
Delirium
1. Manage any underlying cause of delirium by monitoring oxygenation and fluid status,
correcting metabolic or endocrine abnormalities, addressing co-infections, minimizing the use
of medications that may cause or worsen delirium, treating withdrawal from substances,
understanding and minimizing the effects of any harmful drug-drug interactions and
maintaining normal sleep cycles as much as possible (147).
4. When using antipsychotic medications for agitation, consider side-effects that may worsen
symptomatology, including sedation, respiratory or cardiac function, risk of fever or other
immunological abnormalities, or coagulation abnormalities and any potential drug-drug
interactions between these and other medications. Use minimum effective doses of
antipsychotic medications at the lowest frequency and for the shortest duration possible, with
doses adjusted according to age, medical co-morbidities and degree of distress (149). For
severe agitation, low doses of haloperidol (administered orally or by intramuscular injection)
can be considered, while carefully monitoring for adverse effects such as QT prolongation
(150).
6. If the patient remains severely agitated despite the strategies described above,
benzodiazepines can be added, with preference given to those with shorter half-lives and
lower risk of drug-drug interactions (such as lorazepam); lowest doses should be used and
for the shortest duration possible. The intravenous route should be avoided (150).
We recommend providing basic mental health and psychosocial support (MHPSS) for
all persons with suspected or confirmed COVID-19 by asking them about their needs
and concerns, and addressing them (151).
Remarks:
1. Given the stress that COVID-19 may create at individual and family levels, the high
prevalence of common mental health conditions among women in the antenatal and
postpartum period, and the acceptability of programmes aimed at them, interventions for
2. Basic psychosocial support skills are essential for management of all patients and they
represent an integral part of the care to be provided for different groups, including children,
older adults, pregnant women and others affected by COVID-19.
3. This recommendation is consistent with the Inter-Agency Standing Committee briefing note
about mental health and psychosocial aspects of COVID-19 (151) and WHO
recommendations on providing access to support based on psychological first aid principles
to people in acute distress exposed recently to a traumatic event (152).
4. Ask people about their needs and concerns around diagnosis, prognosis, and other social,
family or work-related issues. Listen carefully, try to understand what is most important to the
person at this moment, and help them work out what their priorities are and link them with
relevant resources and services.
5. Give accurate information on the person’s condition and treatment plans in easily understood
and non-technical language, as lack of information can be a major source of stress. Help
people address urgent needs and concerns, and help with decision-making, as necessary.
Help connect people with loved ones and social support, including through phone or internet
as appropriate.
6. MHPSS and follow up should continue after the person is discharged from hospital to ensure
their symptoms are not worsening and they are continuing to do well. This can be provided
through telehealth, where available and appropriate.
7. Parents and caregivers who may need to be separated from their children, and children who
may need to be separated from their primary caregivers, should have access to appropriately
trained health or non-health workers for MHPSS. MHPSS should be appropriately adapted
for the needs of children, taking into consideration their social and emotional development,
learning and behaviour (151).
Remarks:
1. For people who are experiencing symptoms of anxiety, psychosocial support strategies such
as psychological first aid, stress management, and brief psychological interventions based on
the principles of cognitive behavioural therapy should be considered (152, 153).
2. For relieving anxiety causing severe distress that is not responsive to psychosocial support
strategies, benzodiazepines can be considered, specifically in the hospital setting.
Benzodiazepines should only be used with extreme caution with preference for those with
shorter half-lives and lower risk of drug-drug interactions (such as lorazepam). Lowest doses
should be used and for the shortest duration possible; high doses and longer term use should
be avoided (154). Benzodiazepines carry the risks of confusion and respiratory suppression,
may worsen traumatic stress reactions, can produce tolerance and dependence, and are
known to be prescribed indiscriminately in many emergencies.
4. If a person’s anxiety or depressive symptoms persist beyond recovery from COVID-19 and/or
discharge from the hospital, then an underlying anxiety or depressive disorder may be
suspected, and a mental health professional should be consulted and these conditions
should be managed appropriately. Refer to the mhGAP Intervention Guide for mental,
neurological and substance use disorders in non-specialized health settings (155).
5. It is important to ask about thoughts or acts of self-harm, particularly during COVID-19, due to
risk factors for self-harm and suicide such as sense of isolation, loss of a loved one, job, or
financial loss and hopelessness. Remove possible means of self-harm, activate psychosocial
support, follow up with the person, and consult a mental health professional as necessary.
Refer to the mhGAP Intervention Guide for mental, neurological and substance use disorders
in non-specialized health settings (155).
Remarks:
1. Sleep hygiene advice (including avoiding the use of psychostimulants such as caffeine,
nicotine or alcohol), and stress management (including relaxation techniques and
mindfulness practices) are effective in reducing sleep problems and may be
offered. Psychological interventions based on the principles of cognitive behavioural therapy
may also be considered.
2. For people who are hospitalized for COVID-19, additional causes of insomnia may
include environmental factors (e.g. excessive light and noise at night), anxiety,
delirium, agitation, pain or air hunger. Identifying and promptly addressing underlying causes
should be prioritized before using any pharmacological sleep aids.
We recommend when caring for patients with suspected and confirmed COVID-
19 that have underlying NCDs to continue or modify previous medical therapy
according to the patient’s clinical condition.
SARS-CoV-2 uses the ACE 2 receptor for entry into cells. It has been suggested that
antihypertensive drugs that exert their effect by inhibiting ACE or blocking the ACE 2 receptor
may either aggravate or ameliorate the clinical course of patients with COVID-19 (156). To date,
there are no studies that can substantiate this, and it is generally advised to continue these
medications unless there are other reasons to stop these (e.g. hyperkalaemia, hypotension or
acute deterioration in renal function) (157).
As COVID-19 is a novel disease, the rehabilitation needs for patients recovering from COVID-
19 are anticipated based on evidence from the general critical care population. Based on this
evidence, it is expected that acute interventions for the management of patients with severe
and critical COVID-19, including mechanical ventilation, sedation and/or prolonged bed rest,
may result in a range of impairments including (but not limited to) physical deconditioning,
respiratory, swallow, cognitive and mental health impairments (145, 158-168). These symptoms
are collectively referred to as post-intensive care syndrome (PICS) (169). Older people and
patients of all ages with chronic diseases, may be most susceptible to its impacts (170-173).
Patients recovering from severe COVID-19 who did not require admission to an ICU may also
experience some degree of these symptoms (174).
For the following patient groups, routinely assess for mobility, functional,
swallow, cognitive impairments and mental health concerns, and, based on that
assessment, determine discharge readiness, and rehabilitation and follow-up
requirements:
• patients that are in or have been discharged from intensive care;
• older patients that have experienced severe cases; and
• patients that exhibit signs of any of these impairments.
Remark:
Use standardized assessment instruments, where available and appropriate (175) to detect the
presence and severity of impairments related to physical function, respiratory function, cognition,
nutrition, communication, swallow, activities of daily living and psychosocial needs (or any other
impairments). Consider these in the context of the person’s individual situation, including pre-
admission status, social support, home environment and access to rehabilitation follow up.
Particular consideration should be given to older people, those with disability and those with co-
morbidities, who may have more complex requirements (176, 177). Involve the person, family
and caregivers in the assessment and decision-making regarding rehabilitation and discharge
planning.
Remarks:
1. Ensure that appropriate IPC is available at designated rehabilitation areas that are caring for
patients with COVID-19 that remain infectious.
3. When a patient does not require inpatient rehabilitation but would benefit from rehabilitation
follow up post-discharge, refer to outpatient or community-based services according to local
service availability. Consider which options have the least barriers to attendance/service
utilization and, where available and appropriate, refer to services delivered through
telehealth, particularly where IPC measures prevent in-person consultations. Ensure patients
are provided with education and information resources for self-management, especially when
barriers to accessing rehabilitation follow up are anticipated.
Remarks:
2. Rehabilitation programmes should be orientated around patient needs and goals and may
entail exercises; education and advice on self-management strategies (including for
cognition, swallow and activities of daily living); respiratory techniques (such as breathing
exercises and techniques); provision of assistive products; caregiver support and education;
peer-to-peer groups; stress management; and home modification.
4. Where long-term rehabilitation needs associated with severe respiratory illness and PICS are
apparent, such as persisting fatigue, reduced exercise tolerance and difficulty with activities
of daily living, for example, patients may benefit from pulmonary rehabilitation programmes
(or similar) in the community (176). If the etiology of symptoms is unclear, a specialist
rehabilitation assessment can be considered. This may require involvement of relevant
specialists, primary health care providers (general practitioners), rehabilitation professionals,
mental health and psychosocial providers, and social care services for coordinated care.
18. Caring for women with COVID-19 during and after pregnancy
There are limited data on the clinical presentation, and maternal and perinatal outcomes of
COVID-19 disease during or after pregnancy. Current findings should be cautiously
interpreted given the small sample sizes and limitations in study design. As of 24 April 2020,
data show a prevalence and patterns of clinical presentation in pregnancy that are broadly
similar to the general population. But these findings are restricted to women who were
managed in hospitals for any reason, with limited data on women postpartum. Studies varied
in the rigor of ascertaining mother-to-child transmission. So far, there is no confirmed
mother-to-child transmission.
This section builds on existing recommendations from WHO on pregnancy and infectious
diseases and provides additional remarks for the management of pregnant and recently
pregnant women.
We recommend all pregnant women with history of contact with a person with
confirmed COVID-19 be carefully monitored, considering asymptomatic
transmission of COVID-19 may be possible.
Remarks:
1. Counsel pregnant and recently pregnant women about maternal and newborn signs,
including COVID-19 danger signs and maternal perception of decreased fetal movements,
and advise them to seek urgent care if they develop any worsening of illness or other danger
signs, such as danger signs of pregnancy (including: bleeding or leaking fluid from the
vagina, blurry vision, severe headaches, weakness or dizziness, severe abdominal pain,
swelling of face, fingers, feet, inability to tolerate foods or liquids, convulsions, difficulty
breathing, decrease in fetal movements). Update birth preparedness and complication
readiness plans so they know when and where to seek care.
2. In pregnant and postnatal women that are being cared for at home in self-isolation, self-care
interventions should be encouraged. Routine antenatal or postnatal health visits in health
facilities should be postponed, and delivery of antenatal and postnatal counselling and care,
and follow up or other reasons should instead be conducted via alternative platforms such as
home-based, phone or telemedicine (178, 179). For women requiring abortion services,
consider alternate modes of abortion services, including self-management of medical
abortion up to 12 weeks’ gestation, where women have access to accurate information and
to a health care provider at any stage of the process. Postponing abortion care may lead to
increased morbidity and mortality where individuals resort to unsafe abortion practices as
abortion service delivery is time-bound by gestational limits prescribed by the law (180). If
postponed, health visits should be rescheduled until after the period of self-isolation following
national guidelines and advice, and in consultation with the health care provider. See the
WHO Consolidated guideline on self-care interventions for health (181).
3. Counsel women about healthy diet, mobility and exercise, intake of micronutrients for herself
and her infant, tobacco use and second-hand smoke exposure, use of alcohol and other
substances, as per WHO guidelines on antenatal and postnatal care. Clinical enquiry about
the possibility of gender-based violence should be strongly considered, where there is the
capacity to provide a supportive response (including referral where appropriate) and where
the WHO minimum requirements are met. See resource (182).
Remarks:
1. Woman-centred, respectful, skilled care refers to care organized for and provided to all
women in a manner that maintains their dignity, privacy and confidentiality, ensures freedom
from harm and mistreatment, and enables informed choice. During labour and childbirth this
includes a companion of choice, pain relief, mobility during labour and birth position of choice.
2. Screen birth companions using the standardized case definition. If the companion has
suspected or confirmed COVID-19, arrange for an alternative, healthy birth companion in
consultation with the woman. Emphasize to any and all companions the importance of IPC
measures during labour, childbirth and the mother’s and newborn’s postnatal stay in the
health facility, including appropriate training on and use of PPE and movement restriction in
the health care facility.
Remarks:
1. Emergency birth and pregnancy termination decisions are challenging and based on many
factors such as gestational age, severity of maternal condition, and fetal viability and well-
being.
3. Delayed umbilical cord clamping (not earlier than 1 minute after birth) is recommended for
improved maternal and infant health and nutrition outcomes. The risk of transmission of
COVID-19 through blood is likely to be minimal. There is no evidence that delaying cord
clamping increases the possibility of viral transmission from the mother to the newborn. The
proven benefits of a 1–3 minute delay, at least, in clamping the cord outweigh the theoretical,
and unproven, harms.
Pregnant and recently pregnant women who have recovered from COVID-19
and been released from the COVID-19 care pathway, should be enabled and
encouraged to receive routine antenatal, postpartum, or postabortion care, as
appropriate. Additional care should be provided if there are any complications.
1. All pregnant women with or recovering from COVID-19 should be provided with counselling
and information related to the potential risk of adverse pregnancy outcomes.
2. Women’s choices and rights to sexual and reproductive health care should be respected
regardless of COVID-19 status, including access to contraception and safe abortion to the full
extent of the law (180).
19. Feeding and caring for infants and young children of mothers
with COVID-19
Relatively few cases have been reported of infants confirmed with COVID-19; those that have
been reported experienced mild illness. Of 115 mother-child pairs from 17 articles where the
mother is confirmed to be infected with COVID-19, 13 children had COVID-19 (4 breastfed, 5
formula-fed, 2 mix-fed, 2 unreported feeding practice). Twenty mothers had breastmilk
samples tested for the presence of SARS-CoV-2 RNA particles by RT-PCR; 7 of them had
children with COVID-19 (2 breastfed,1 formula fed, 2 mix-fed, 2 unreported). Of the 20 with
breastmilk tested, 18 had negative results and 2 had positive results. One of the two mothers
whose breastmilk sample was positive for SARS-CoV-2, had a mix-fed child who was not
infected with COVID-19; the other one had a child with COVID-19 (feeding practice was not
reported) (185-195).
Breastfeeding protects against morbidity and death in the post-neonatal period and throughout
infancy and childhood. The protective effect is particularly strong against infectious diseases
that are prevented through both direct transfer of antibodies and other anti-infective factors
and long-lasting transfer of immunological competence and memory. See WHO Essential
newborn care and breastfeeding (196). Therefore, standard infant feeding guidelines should
be followed with appropriate precautions for IPC.
Recommendations on the care and feeding of infants whose mothers have suspected or
confirmed COVID-19 promote the health and well-being of the mother and infant. Such
recommendations must consider not only the risks of infection of the infant with the COVID-
19 virus, but also the risks of serious morbidity and mortality associated with not breastfeeding
or the inappropriate use of breastmilk substitutes as well as the protective effects of skin-to-
skin contact and kangaroo mother care. In light of the current evidence, WHO has concluded
that mothers with suspected or confirmed COVID-19 should not be separated from
their infants. Mother-infant contact and holding enhances thermoregulation and other
physiological outcomes, significantly reduces mortality and morbidity, and improves child and
parental attachment. Overall, the recommendation to keep mothers and their children together
is based on several important benefits that outweigh the potential (and likely mild) harms
of COVID-19 transmission to the child.
WHO recognizes that the recommendation for an infected mother to be in close contact with her
baby may appear to contradict other IPC measures that include isolation of persons infected with
COVID-19 virus (41). However, the balance of risks is significantly different for infants than for
adults. In infants, the risk of COVID-19 infection is low, the infection is typically mild or
asymptomatic, and the consequences of not breastfeeding or separation of mother and child can
be significant. At this point it appears that COVID-19 in infants and children represents a much
lower risk to survival and health than the other infections and conditions that breastfeeding is
protective against. This protection is especially important when health and other community
services are themselves under pressure. In contrast, the risks associated with COVID-19 in
adults are much higher and more severe. Improved communication is needed to address the
uncertainties and confusion among programme managers, health workers and communities on
this issue.
Early and uninterrupted skin-to-skin contact between mothers and infants should be facilitated and
encouraged as soon as possible after birth, while applying necessary measures for IPC. This applies
also to infants who are born preterm or low birth weight.
If the newborn or infant is ill and requires specialist care (such as neonatal unit), arrangements
should be made to allow the mother free access to the unit, with appropriate IPC measures.
Earlier initiation of breastfeeding results in greater benefits. This may be relevant to mothers who
give birth by caesarean section, after an anaesthetic, or those who have medical instability that
precludes initiation of breastfeeding within the first hour after birth.
During early Infants should be breastfed exclusively during the first 6 months after birth, as breastmilk provides
childhood all the nutrients and fluids they need.
From 6 months of age, breastmilk should be complemented with a variety of adequate, safe and
nutrient-dense foods. Breastfeeding should continue up to 2 years of age or beyond.
Breastfeeding counselling, basic psychosocial support and practical feeding support should be
provided to all pregnant women and mothers with infants and young children if they or their infants
and young children have suspected or confirmed COVID-19 infection.
If feeding is In situations when severe illness in a mother prevents her from caring for her infant or prevents her
interrupted from continuing direct breastfeeding, mothers should be encouraged and supported to express milk,
and the breastmilk provided safely to the infant, while applying appropriate IPC measures.
In the event that the mother is too unwell to breastfeed or express breastmilk, explore the viability
of feeding with donor human milk. If this is not possible, consider wet nursing (defined as another
woman breastfeeds the child) or appropriate breastmilk substitutes, informed by feasibility, safety,
sustainability, cultural context, acceptability to mother and service availability.
Practices the Perform frequent hand hygiene with soap and water or alcohol-based hand rub,
mother should especially before contact with her child.
perform during
all infant and Perform respiratory hygiene: sneeze or cough into a tissue and immediately dispose of the
childcare tissue. Hands should immediately be washed with soap and water or alcohol-based hand rub.
Clean and disinfect surfaces with which the mother has been in contact.
Wear a medical mask until symptom resolution and criteria for release from isolation have been
met.
Additionally, breastfeeding mothers should be helped to clean her chest with soap and water if she
has been coughing on it before breastfeeding. She does not need to wash her breasts prior to
every breastfeed.
While mothers are recommended to wear medical masks, if the mother does not have a medical
mask, she should still be encouraged to continue breastfeeding as the benefits of breastfeeding
outweigh the potential risks of transmission of the virus when breastfeeding while applying other
IPC measures.
Best practices Health facilities providing maternity and newborn services should enable a mother to breastfeed for
for breast- as often and for as long as she wishes. Minimizing disruption to breastfeeding will require health
feeding care practices that enable a mother to breastfeed.
All mothers should receive practical support to enable them to initiate and establish breastfeeding
and manage common breastfeeding difficulties. This support should be provided by appropriately
trained health care professionals and community-based lay and peer breastfeeding counsellors.
There should be no promotion of breastmilk substitutes, feeding bottles and teats, pacifiers or
dummies in any part of facilities providing maternity and newborn services, or by any of the staff.
Health facilities and their staff should not give feeding bottles and teats or other products that are
within the scope of the International Code of Marketing of Breast-milk Substitutes and its subsequent
related WHA resolutions, to infants.
If the mother is too unwell to breastfeed or express breastmilk, explore the best alternatives to
breastfeeding a newborn or young infant, in priority order, as follows: 1) donor human milk should
be fed if available from a human milk bank; 2) if supplies are limited, prioritize donor human milk for
preterm and low birthweight newborns; 3) wet nursing may be an option depending on acceptability
to mothers and families, availability of wet nurses and services to support mothers and wet nurses.
COVID-19 testing of a woman who is a potential wet nurse is not required. Prioritize wet nurses for
the youngest infants. In settings where HIV is prevalent, prospective wet nurses should undergo
HIV counselling and rapid testing where available. In the absence of testing, if feasible, undertake
HIV risk assessment. If HIV risk assessment or counselling is not possible, facilitate and support
wet nursing; 4) breastmilk substitutes may be used as a last resort.
Older age has been reported as a risk factor for increased mortality in those affected by
COVID-19. Other risk factors that have been reported are: smoking, diabetes, hypertension,
cerebrovascular disease, cancer and chronic lung disease. Since older people are often
affected by these conditions as well, they are potentially at the highest risk for fatality. Those
with frailty are one of the most vulnerable populations. Refer to the WHO guidance
Integrated care for older people (ICOPE) (197) for person-centred and coordinated model of
care.
We recommend that older people be screened for COVID-19 at the first point of
access to the health system, be recognized promptly if they are suspected to
have COVID-19 and treated appropriately according to established COVID-19
care pathways. This should occur in all settings where older people may seek
care; included but not limited to facility-based emergency units, primary care,
prehospital care settings and LTCFs.
Remark:
Older patients may present with atypical symptoms (including delirium) of COVID-19 (see Table
1); health workers should take this into account during the screening process.
Identify if there is an advance care plan for patients with COVID-19 (such as
desires for intensive care support) and respect their priorities and preferences.
Tailor the care plan to be in line with patients’ expressed wishes and provide
the best care irrespective of treatment choice.
Remarks:
2. Over 20% of adults over 60 years have pre-existing mental or neurological conditions for
which they may already be taking medications before infection (198). If a person has a
previously diagnosed mental or neurological condition and is already on medications,
consider how these medications (or withdrawal from them) may affect their COVID-19
symptoms. Stopping or adjusting the dosage of medications in people with COVID-19 are
decisions that require careful risk-benefit analyses and when possible, consultation with a
specialist is advised.
Remarks:
1. Physiological changes with age lead to declines in intrinsic capacity such as malnutrition,
cognitive decline, depressive symptoms, and those conditions interact at several levels.
These interactions require an integrated approach to the screening, assessment and
management of older people (197).
2. Hearing and vision impairments become more prevalent among older adults and may pose a
communication barrier, especially when masks prevent lip reading and decrease vocal clarity.
Cognitive decline may also need to be considered when communicating with older patients.
Such impairments should be identified early so that health workers involved in their care can
adjust their communication accordingly (199).
3. Older people who experience COVID-19, including those admitted to ICU and/or treated
with protracted oxygen therapy and bed rest, are more likely to experience pronounced
functional decline and require coordinated rehabilitation care after acute hospitalization
(see Chapter 17: Rehabilitation for patients with COVID-19).
4. Ensure that chronic infections are diagnosed and treated appropriately in older people. Other
infections such as TB may mimic or co-exist with COVID-19 and therefore pass
unrecognized, causing increased mortality (38, 39, 41).
Palliative care is a multifaceted, integrated approach to improving the quality of life of adults and
paediatric patients and their families facing the problems associated with life-threatening illness
such as COVID-19. Palliative care focuses on prevention and relief of suffering by means of early
identification, assessment and treatment of physical, psychosocial and spiritual stressors. Palliative
care includes but is not limited to end-of-life care (200). Palliative interventions should be integrated
with curative treatment (200). Basic palliative care, including relief of dyspnoea or other symptoms
and social support, should be practised by all doctors, nurses, social workers and others caring for
persons affected by COVID-19 (200, 201). Refer to the WHO guide Integrating palliative care and
symptom relief into responses to humanitarian emergencies and crises (200).
2. Palliative care includes but is not limited to end-of-life care. Palliative interventions should be
integrated with curative treatment. Basic palliative care, including relief of dyspnoea or other
symptoms and social support, should be practised by all doctors, nurses, social workers and
others caring for persons affected by COVID-19.
3. In hospitals, palliative care does not require a separate ward or department. Palliative care
can be provided in any setting.
4. Consider opioids and other pharmacologic and non-pharmacologic interventions for relief of
dyspnoea that is refractory to treatment of the underlying cause and/or as part of end-of-life
care (202). The narrow therapeutic margin of opioids in the management of dyspnoea
requires that opioids are prescribed in accordance with evidence-based treatment protocols
and that patients are closely monitored to prevent negative unintended effects due to
inappropriate use of opioids. Providers should reference their institutional standards
regarding the potential use of opioids for dyspnoea in patients with COVID-19.
Equal moral respect: Every person is equally valuable. Treatment and care decisions
should be based on medical need and not on irrelevant or discriminatory features such as
ethnicity, religion, sex, age, disability or political affiliation. Patients with similar health
problems or symptoms must receive equal treatment and care. Showing moral respect
means involving patients and their caregivers in decision-making to the greatest extent
possible, explaining options and limitations in treatment.
Duty of care: Every patient is owed the best possible care and treatment available in the
circumstances. Even when resources need to be rationed during a crisis, health care
professionals and frontline workers have a duty of care to promote their patients’ welfare
within available resources. Health care professionals and frontline workers are also owed a
duty of care. In this regard, appropriate PPE for health care professionals and frontline
workers should be provided to promote their safety and well-being. This is a benefit to them
but also to the whole of society by ensuring that they are available to support the clinical
response for as long as possible.
Non-abandonment: It follows from consideration of equal moral respect and duty of care,
that no person in need of medical care should ever be neglected or abandoned. Care will
Protection of the community: Appropriate IPC should be in place, respected and enforced.
Such actions protect patients, health care professionals and the community. During a
pandemic the focus should be on both clinical care for patients and the promotion of public
health.
Confidentiality: All communications between patient and clinician must remain confidential
except in the case of compelling public health concerns (e.g. contact tracing and surveillance
etc.) or other accepted justifications for breach of confidentiality. Private individual
information must be kept secure unless it is a justified breach.
We recommend that hospitals and health systems at local, regional, national and
global level plan prepare and be ready to surge clinical care capacity (staff, structure,
supplies and systems) in order to be able to provide appropriate care of all COVID-19
patients and maintain essential health services (33, 205).
Remarks:
1. Personnel familiar with the medical triage criteria and allocation protocols, who are distinct
from the clinical treating team are one option. Allocation decisions should be done according
to the established plan and regularly reviewed. If necessary, there should be a reallocation of
a resource that was previously allocated where it is not proving beneficial.
2. For example, the aim might be to ensure the best possible use of limited resources based
upon chosen medical criteria. Triage criteria should seek to balance medical utility and equity,
and ease of implementation. The same criteria should be applied for all patients with similar
levels of need, regardless of COVID-19 status.
Remarks:
1. It should be clear what the “tipping point” is to change to pandemic allocation (e.g. a
declaration by a ministry of health, or hospitals reaching ICU bed and ventilator capacity).
This should take into account maximizing surge clinical capacity.
2. Whatever method is chosen should be subject to a fair process, such as using the following
procedural principles:
Remark:
Caregivers are at risk for the same types of psychological, social and spiritual distress as
patients. They are also at risk for becoming infected. Basic mental health and psychosocial
support should be provided for all caregivers by asking them about their needs and concerns,
and addressing them (206).
Remarks:
1. The primary goal is to identify all deaths due to COVID-19. A death due to COVID-19 is
defined for surveillance purposes as a death resulting from a clinically compatible illness, in a
probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that
cannot be related to COVID-19 disease (e.g. trauma). There should be no period of complete
recovery from COVID-19 between illness and death. A death due to COVID-19 may not be
attributed to another disease (e.g. cancer) and should be counted independently of pre-
existing conditions that are suspected of triggering a severe course of COVID-19.
2. Specification of the causal sequence leading to death in Part 1 of the certificate is important.
For example, in cases when COVID-19 causes pneumonia, sepsis and acute respiratory
distress; then pneumonia, sepsis and acute respiratory distress should be included, along
with COVID-19, in Part 1. Certifiers should include as much detail as possible based on their
knowledge of the case, from medical records, or about laboratory testing (207).
There are many ongoing clinical trials testing various potential antivirals; these are registered
on https://clinicaltrials.gov/, the Chinese Clinical Trial Registry
(http://www.chictr.org.cn/abouten.aspx) and on the WHO website: Living mapping and living
systematic review of COVID-19 studies (208). For more information about the WHO
research roadmap see https://www.who.int/teams/blueprint/covid-19
Remarks:
1. Member States are invited to contribute anonymized clinical data to the WHO Global COVID-
19 Clinical Data Platform; contact: COVID_ClinPlatform@who.int to get log-in credentials.
This will serve to inform the public health and clinical response.
2. Three case record forms (CRFs) are now available: These can be accessed on the WHO
website (209).
• Rapid CRF
• Pregnancy CRF
• Multisystem inflammatory syndrome temporally associated with COVID-19 CRF.
The WHO Solidarity trial is a randomized clinical trial that is a currently enrolling.
For more information see the WHO website (211).
Remark:
Older age is reported to be a predictor of mortality in patients with COVID-19. The systematic
exclusion of older adults from research activities or from accessing investigational therapeutic
agents is not justified (204).
Table A3.1 Essential package of palliative care: interventions, medicines, equipment, human
resources and social supports
Inputs
Interventions Medicinesa Equipment Human Social
resourcesb supports
Prevention and – Amitriptyline, oral – Pressure- – Doctors (with
relief of pain or – Bisacodyl (senna), oral reducing basic palliative
other physical mattresses care training)
– Dexamethasone, oral and
suffering,c acute
injectable – Nasogastric – Nurses (with
or chronic, drainage and basic palliative
related to
– Diazepam, oral and injectable
feeding tubes care training)
COVID-19 – Diphenhydramine
(chlorpheniramine, cyclizine, or
– Urinary – Community
catheters health workers
dimenhydrinate), oral and
– Opioid lock (if available)
injectable
boxes
– Fluconazole, oral
– Fluoxetine, oral
– Flashlights with
rechargeable
– Furosemide, oral and injectable batteries (if no
– Haloperidol, oral and injectable access to
– Hyoscine butylbromide, oral and electricity)
injectable – Adult diapers or
– Ibuprofen (naproxen, diclofenac, cotton and
or meloxicam), oral plastic
– Lactulose (sorbitol or
polyethylene glycol), oral
– Loperamide, oral
– Metaclopramide, oral and
injectable
– Metronidazole, oral, to be
crushed for topical use
– Morphine, oral immediate release
and injectable
– Naloxone, injectable
– Omeprazole, oral
– Ondansetron, oral and injectabled
– Oxygen
– Paracetamol, oral
– Petroleum jelly
a
Based on WHO Model List of Essential Medicines (2015). Acceptable alternative medicines are in parentheses: ( )
b
Doctors may be local or foreign and may be surgeons, anaesthesiologists, intensivists, infectious disease specialists,
paediatricians, general practitioners, palliative care specialists, or others. Nurses may include nurse-anaesthetists.
c
Other physical suffering includes breathlessness, weakness, nausea, vomiting, diarrhoea, constipation, pruritus, bleeding,
wounds and fever.
d
Only at hospitals that provide cancer chemotherapy or radiotherapy.
e
Psychological suffering includes anxiety, depressed mood, confusion or delirium, dementia and complicated grief.
f
Only for patients living in extreme poverty and for one caregiver per patient. Includes cash transfers to cover housing,
children’s school tuition, transportation to health care facilities or funeral costs; food packages; and other in-kind support
(blankets, sleeping mats, shoes, soap, toothbrushes, toothpaste).
Source: Integrating palliative care and symptom relief into responses to humanitarian emergencies and crises: a WHO guide
(2018).
1. Country & technical guidance – coronavirus disease (COVID-19) [website]. Geneva: World Health Organization; 2020
(https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance).
2. Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults
with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020. Epub 2020/04/01.
3. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of
Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-77. Epub 2017/01/20.
4. Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving Sepsis Campaign International Guidelines for the Management of
Septic Shock and Sepsis-associated Organ Dysfunction in Children. Intensive Care Med. 2020;46(Suppl 1):10-67. Epub 2020/02/08.
5. Burke RM, Midgley CM, Dratch A, Fenstersheib M, Haupt T, Holshue M, et al. Active monitoring of persons exposed to patients with confirmed COVID-
19 — United States, January–February 2020. MMWR Morb Mortal Wkly Rep. 2020.
6. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA. 2020. Epub 2020/03/05.
7. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly
Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020. Epub 2020/03/10.
8. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020. Epub 2020/03/23.
9. Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person
transmission during the incubation period. J Infect Dis. 2020. Epub 2020/02/19.
10. Huang R, Xia J, Chen Y, Shan C, Wu C. A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. Lancet Infect Dis.
2020;20(5):534-5. Epub 2020/03/03.
11. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. 2020;20(4):410-1.
Epub 2020/02/23.
12. Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP, et al. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg
Infect Dis. 2020;26(5):1052-4. Epub 2020/02/25.
13. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. MMWR
Morb Mortal Wkly Rep. 2020;69(14):411-5. Epub 2020/04/10.
14. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of
2019 novel coronavirus diseases (COVID-19) – China. China CDC Weekly. 2020;2(8):113-22.
15. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, Severity and Mortality Associated with COPD and
Smoking in Patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS One. 2020;15(5):e0233147. Epub 2020/05/12.
16. Tobacco use and COVID-19. 11 May 2020 Statement. Geneva: World Health Organization; 2020 (https://www.who.int/news-room/detail/11-05-2020-
who-statement-tobacco-use-and-covid-19, accessed14 May 2020).
17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
2020;395(10223):497-506. Epub 2020/01/28.
18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study. Lancet. 2020;395(10229):1054-62. Epub 2020/03/15.
19. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-
CoV-2 Infection. JAMA. 2020. Epub 2020/04/23.
20. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.
JAMA Neurol. 2020. Epub 2020/04/11.
21. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med.
2020. Epub 2020/04/16.
22. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective
study. BMJ. 2020;368:m1091. Epub 2020/03/29.
23. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J
Med. 2020. Epub 2020/04/29.
24. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with
COVID-19. Thromb Res. 2020. Epub 2020/04/16.
25. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol.
2020;19(5):383-4. Epub 2020/04/05.
26. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI
Features. Radiology. 2020;201187. Epub 2020/04/02.
27. Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin
Infect Dis. 2020. Epub 2020/03/01.
28. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr
Pulmonol. 2020;55(5):1169-74. Epub 2020/03/07.
29. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA. 2020. Epub
2020/02/15.
30. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663-5. Epub 2020/03/19.
31. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet.
2020. Epub 2020/05/11.
32. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep.
2020;69(14):422-6. Epub 2020/04/10.
33. Operational considerations for case management of COVID-19 in health facility and community. Geneva: World Health Organization; 2020
(https://www.who.int/publications-detail/operational-considerations-for-case-management-of-covid-19-in-health-facility-and-community, accessed 13
May 2020).
34. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled
Nursing Facility. N Engl J Med. 2020. Epub 2020/04/25.